Editorial
What words would you fear more, "You have cancer" or "You have a urinary tract infection (UTI)"? I believe most people would fear the words "You have cancer" because many types of cancer are untreatable and are associated with death. Unfortunately, due the escalating rates of antibiotic resistance the world is entering an era of "untreatable" UTIs where just like cancer, a UTI can also be associated with death. Pharmacists need to have an awareness of the global rates of antibiotic resistance because every multidrug-resistant organism (MDRO) is just a plane ride away. Dr. Marc Sprenger, director of the World Health Organization (WHO) Antimicrobial Resistance Secretariat stated, "Some of the world's most common-and potentially most dangerousinfections are proving drug-resistant, and most worrying of all, pathogens don't respect national borders."
1 Consider the following four scenarios and the impact it might have on your antibiotic decisions for a hospitalized patients.
• Antibiotics are societal drugs and are unlike any other drug. The more we use antibiotics the less effective they become, thus reducing our ability to use that antibiotic in the future. Addressing antibiotic overuse is challenging because patients and healthcare providers (HCP) have insufficient incentives to act in ways that would conserve antibiotic use. Both the public and many healthcare professionals seem to be blissfully unaware of the escalating rates of antibiotic resistance. Patients continue to pressure HCP for antibiotics. HCP continue to overprescribe antibiotics "just-in-case" there is an infection. According to the Centers for Disease Control and Prevention (CDC), 30% of antibiotics prescribed by HCP are unnecessary. 6 To make matters worse, unnecessary antibiotic use can result in the patient developing Clostridium difficile infection (CDI) which can be associated with death. In 2008, the Infectious Disease Society of America (IDSA) issued a call to action by asking HCP to develop a grassroots effort to increase awareness. 7 IDSA recommended Antibiotic Stewardship Programs (ASPs) led by infectious diseases (ID) physicians and pharmacists to provide guidance and management of antibiotics in hospitals. 8 While many hospitals implemented ASPs, many did not. It took almost 10 years to realize that "optional" ASP is not working.
In response to the escalating rates of infections due to MDROs and the dwindling number of new antibiotics, the Joint Commission in 2017 required hospitals to establish ASPs for accreditation. This requirement places pharmacists in a unique position to step up and answer the call to action to address resistance and the overuse of antibiotics with the implementation of ASPs. In a new report titled "The Expanding Role of ASP in Hospitals in the United States: Lessons Learned from a Multisite Qualitative Study" the authors make the case for expansion of personnel to amplify the ASP's impact and to integrate information technology resources into daily workflow to improve efficiency. 9 The researchers interviewed key personal from established ASPs to identify strategies to overcome barriers in the face of ongoing regulatory and accreditation requirements. While the traditional model of ASP consists of ID trained pharmacists and physicians making ASP interventions throughout the hospital, they acknowledge there are problems with this model. In large medical centers with greater than 1000 beds, as many as 500 patients a day may be receiving an antibiotic. ASPs do not have sufficient resources to review antibiotic therapy on that many patients. The authors describe how to expand the reach of ASP by incorporating all pharmacists in ASP.
I like to say ASP steers the ship but we need all hands on deck to complete the journey. The authors cite our study from The Ohio State University Wexner Medical Centers ASP where we incorporated all pharmacists 24/7 to assist in the management of patients with Staphylococcus aureus bacteremia. 10 The ASP team was steering the ship (developed the evidence based S aureus bundle) but all hands (every pharmacist) were on deck. This approach not only amplified ASP impact on patient care; it also improved clinical outcomes. I frequently hear comments that this approach only works in large hospitals that have ID physicians and pharmacists leading ASP. I am quick to cite the success of ASP in South Africa where there are only about 20 ID physicians in the country and there are no ID trained pharmacists. Despite these barriers, pharmacists initiated ASP with 5 low-hanging fruit interventions in 47 hospitals across South Africa.
11
Antibiotic use decreased 18%. The pharmacists had only 1 hour a day dedicated to ASP interventions. The success of the pharmacist-led ASP in South Africa is a testimony to the saying "where there is a will there is a way." All hospital ASP's have barriers but every day spent discussing these barriers without actions is another day of antibiotic misuse in patients.
I believe every pharmacist can make meaningful contributions to ASP. The following examples describe ASP roles for pharmacists working in different positions within the pharmacy.
• • IV room: Pharmacists can always identify the most "popular" IV antibiotic and recent trends or changes in prescribing patterns. This information can help ASP identify problems as they develop within the hospital. • • Order entry/verification of orders: Upon receiving an order for 3 new antibiotics, the pharmacist can review the medication profile for proton pump inhibitors (PPIs) and call the physician to recommend discontinuing the PPI to decrease the risk of CDI. The ASP should develop a script for the pharmacist and provide literature references to support the intervention. The pharmacist should document the ASP intervention. • • Clinical specialists: Non-ID trained specialists should manage antibiotic therapy on their patients because they make daily rounds on the patients and work with the medical team as decisions are made. ASP should provide education to the specialists to empower them to make antibiotic approvals for restricted or "protected" antibiotics. Soon the requirements for ASP will expand from the hospital setting to the outpatient setting. This presents an amazing ASP opportunity for pharmacists in every type of setting, not just the hospital setting. Collaborative practice agreements are providing new opportunities for pharmacists to practice at the "top of their license" and to support appropriate use of antibiotics. Antibiotic resistance impacts everyone. At some point, it may be you, your parents, spouse, child, or friend who will acquire an infection due to a MDRO. Antibiotic stewardship is for our children's children. Pharmacists can step up and embrace the call to action for antibiotic stewardship. If not us, then who?
